[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 4 of about 4
1. Armstrong DA, Phelps LN, Vincenti MP: CCAAT enhancer binding protein-beta regulates matrix metalloproteinase-1 expression in interleukin-1beta-stimulated A549 lung carcinoma cells. Mol Cancer Res; 2009 Sep;7(9):1517-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCAAT enhancer binding protein-beta regulates matrix metalloproteinase-1 expression in interleukin-1beta-stimulated A549 lung carcinoma cells.
  • In this study, we examined the activation of MMP-1 gene expression in A549 lung carcinoma cells stimulated with the inflammatory cytokine interleukin-1beta (IL-1beta).
  • An established CEBP element in the MMP-1 promoter was found to be required for basal and IL-1beta-induced transcription.
  • DNA affinity chromatography studies showed that the LAP1, LAP2, and LIP isoforms of CEBPB bind to the IL-1beta-responsive CEBPB site in the MMP-1 promoter.
  • Exogenous expression of the LAP1 and LAP2 isoforms stimulated the MMP-1 promoter, whereas LIP had no effect.
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression / drug effects. Gene Knockdown Techniques. Humans. Matrix Metalloproteinase 10 / biosynthesis. Matrix Metalloproteinase 10 / genetics. Matrix Metalloproteinase 3 / biosynthesis. Matrix Metalloproteinase 3 / genetics. Oligonucleotides / metabolism. Phosphorylation. Promoter Regions, Genetic. RNA Interference

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus┬« - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19723873.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-beta; 0 / Interleukin-1beta; 0 / Oligonucleotides; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.22 / Matrix Metalloproteinase 10; EC 3.4.24.7 / MMP1 protein, human; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


2. Shao J, Qiao L, Janssen RC, Pagliassotti M, Friedman JE: Chronic hyperglycemia enhances PEPCK gene expression and hepatocellular glucose production via elevated liver activating protein/liver inhibitory protein ratio. Diabetes; 2005 Apr;54(4):976-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conversely, chronic hyperglycemia is accompanied by progressive increases in basal HGP and is a major contributor to hyperglycemia in both type 1 and type 2 diabetes by mechanisms that are poorly understood.
  • Although total CCAAT/enhancer-binding protein beta (C/EBPbeta) protein levels were suppressed, 20 mmol/l glucose increased the liver activating protein (LAP; an active isoform of C/EBPbeta)/liver inhibitory protein (LIP; an inhibitory isoform of C/EBPbeta) ratio significantly.
  • Using transient transfection to manipulate the LAP/LIP ratio, we also demonstrate a direct relationship between this ratio and PEPCK promoter activity.
  • An increased LAP/LIP ratio not only enhanced cAMP- and dexamethasone-induced PEPCK gene expression but also impaired the repressive effect of insulin.
  • Because prolonged hyperglycemia increases the LAP/LIP ratio and can potentiate hormone induction of PEPCK transcription, our results suggest that a hyperglycemia-driven increased LAP/LIP ratio may be a critical molecular event in the pathogenesis of increased HGP in diabetes.
  • [MeSH-minor] Animals. Carcinoma, Hepatocellular. Cell Line, Tumor. Dose-Response Relationship, Drug. Gene Expression. Glucose / pharmacology. Signal Transduction. Time Factors

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793235.001).
  • [ISSN] 0012-1797
  • [Journal-full-title] Diabetes
  • [ISO-abbreviation] Diabetes
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-42938
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-beta; EC 4.1.1.32 / Phosphoenolpyruvate Carboxykinase (GTP); IY9XDZ35W2 / Glucose
  •  go-up   go-down


3. Housman TS, Berg D, Most SP, Odland PB, Stoddard E: Repair of the philtrum: an illustrative case series. J Cutan Med Surg; 2008 Nov-Dec;12(6):288-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Lip / surgery. Lip Neoplasms / surgery. Mohs Surgery. Skin Neoplasms / surgery. Skin Transplantation. Surgical Flaps
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / therapeutic use. Dermabrasion. Female. Follow-Up Studies. Glucocorticoids / administration & dosage. Glucocorticoids / therapeutic use. Humans. Injections, Intralesional. Male. Middle Aged. Postoperative Complications / drug therapy. Time Factors. Treatment Outcome. Triamcinolone / administration & dosage. Triamcinolone / therapeutic use

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TRIAMCINOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317951.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Glucocorticoids; 1ZK20VI6TY / Triamcinolone
  •  go-up   go-down


Advertisement
4. McDonald C, Laverick S, Fleming CJ, White SJ: Treatment of actinic cheilitis with imiquimod 5% and a retractor on the lower lip: clinical and histological outcomes in 5 patients. Br J Oral Maxillofac Surg; 2010 Sep;48(6):473-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of actinic cheilitis with imiquimod 5% and a retractor on the lower lip: clinical and histological outcomes in 5 patients.
  • Imiquimod 5% (Aldara, 3M Healthcare Ltd.) is a topically applied immune response modifier used in the treatment of superficial basal cell carcinoma, actinic keratosis, and genital warts.
  • Each patient was provided with a specially designed lower lip retractor to prevent spread of the cream.
  • The lower lip was biopsied 4 weeks later, and histologically the dysplastic changes had been reversed in all 5 patients.
  • The lip retractor was well-tolerated, and prevented spread of the cream.
  • Our lip retractor is a simple and cost-effective method of isolating the lower lip and allowing application of topical agents.
  • The method could equally well be used for agents other than imiquimod.
  • [MeSH-major] Aminoquinolines / administration & dosage. Cheilitis / drug therapy. Dental Instruments. Interferon Inducers / administration & dosage

  • Genetic Alliance. consumer health - Actinic Cheilitis.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19836865.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G84/6410
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Interferon Inducers; P1QW714R7M / imiquimod
  •  go-up   go-down






Advertisement